---
figid: PMC3876281__nihms-549624-f0001
figtitle: Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in
  Lung Cancer
organisms:
- Homo sapiens
- Mus musculus
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3876281
filename: nihms-549624-f0001.jpg
figlink: /pmc/articles/PMC3876281/figure/F1/
number: F1
caption: In drug-sensitive cancers (left), the mutant oncogene exerts unilateral control
  over RAS, MEK/ERK, and PI3K/AKT pathway signaling. When inhibited by the appropriate
  TKI, these pathways are suppressed, resulting in cell cycle arrest and apoptosis.
  In drug-resistant cancers with a bypass track (right), the secondary RTK reactivates
  the signaling of at least one of the key downstream pathways, whereas the primary
  oncogene remains inhibited. Sustained activation of these pathways leads to continued
  cell proliferation and survival in the presence of TKI.
papertitle: Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition
  in Lung Cancer.
reftext: Matthew J. Niederst, et al. Sci Signal. ;6(294):10.1126/scisignal.2004652.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9598509
figid_alias: PMC3876281__F1
figtype: Figure
redirect_from: /figures/PMC3876281__F1
ndex: a054e53e-ded5-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3876281__nihms-549624-f0001.html
  '@type': Dataset
  description: In drug-sensitive cancers (left), the mutant oncogene exerts unilateral
    control over RAS, MEK/ERK, and PI3K/AKT pathway signaling. When inhibited by the
    appropriate TKI, these pathways are suppressed, resulting in cell cycle arrest
    and apoptosis. In drug-resistant cancers with a bypass track (right), the secondary
    RTK reactivates the signaling of at least one of the key downstream pathways,
    whereas the primary oncogene remains inhibited. Sustained activation of these
    pathways leads to continued cell proliferation and survival in the presence of
    TKI.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Akt1
  - Mdk
  - Crtc1
  - Ephb2
  - Mapk1
  - EGFR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CRTC1
  - EPHB2
  - MAPK1
  - MAPK3
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Ras64B
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Crtc
  - Tor
  - Erk7
  - rl
  - CycE
  - cyc
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
